BK polyomavirus viremia and antibody responses of pediatric kidney transplant recipients in Finland

2018 ◽  
Vol 23 (1) ◽  
pp. e13324 ◽  
Author(s):  
Jenni Miettinen ◽  
Irmeli Lautenschlager ◽  
Fabian Weissbach ◽  
Marion Wernli ◽  
Eeva Auvinen ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Antibody Responses ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Bk Polyomavirus

scholarly journals BK Polyomavirus Micro-RNAs: Time Course and Clinical Relevance in Kidney Transplant Recipients

Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 351
Author(s):  
Baptiste Demey ◽  
Véronique Descamps ◽  
Claire Presne ◽  
Francois Helle ◽  
Catherine Francois ◽  
...  
Keyword(s):  
Viral Replication ◽  
Kidney Transplant ◽  
Clinical Relevance ◽  
Graft Loss ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Post Transplantation ◽  
Bk Polyomavirus ◽  
Micro Rnas

Background: Kidney transplant recipients (KTRs) are exposed to a high risk of BK polyomavirus (BKPyV) replication, which in turn may lead to graft loss. Although the microRNAs (miRNAs) bkv-miR-B1-3p and bkv-miR-B1-5p are produced during the viral cycle, their putative value as markers of viral replication has yet to be established. In KTRs, the clinical relevance of the changes over time in BKPyV miRNA levels has not been determined. Methods: In a retrospective study, we analyzed 186 urine samples and 120 plasma samples collected from 67 KTRs during the first year post-transplantation. Using a reproducible, standardized, quantitative RT-PCR assay, we measured the levels of bkv-miR-B1-3p and bkv-miR-B1-5p (relative to the BKPyV DNA load). Results: Detection of the two miRNAs had low diagnostic value for identifying patients with DNAemia or for predicting DNAuria during follow-up. Seven of the 14 KTRs with a sustained BKPyV infection within the first year post-transplantation showed a progressive reduction in the DNA load and then a rapid disappearance of the miRNAs. DNA and miRNA loads were stable in the other seven KTRs. Conclusions: After the DNA-based diagnosis of BKPyV infection in KTRs, bkv-miR-B1-3p and bkv-miR-B1-5p levels in the urine might be valuable markers for viral replication monitoring and thus might help physicians to avoid an excessive reduction in the immunosuppressive regimen.

Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study

2019 ◽  
Vol 21 (2) ◽  
pp. e13058 ◽  
Author(s):  
Nicolas Keller ◽  
Simon Duquennoy ◽  
Anne Conrad ◽  
Samira Fafi‐Kremer ◽  
Emmanuel Morelon ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Kidney Transplant ◽  
Clinical Utility ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Bk Polyomavirus

Role of the Early Association of a mTOR Inhibitor and Tacrolimus in BK Polyomavirus Infection in Kidney Transplant Recipients

2018 ◽  
Vol 102 ◽  
pp. S566
Author(s):  
Veronica Lopéz ◽  
Teresa Vazquez ◽  
Cristina Jironda ◽  
Mercedes Cabello ◽  
Juana Alonso ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Mtor Inhibitor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Bk Polyomavirus

scholarly journals Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients

PLoS ONE ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. e0177339 ◽  
Author(s):  
David DeWolfe ◽  
Jinal Gandhi ◽  
Matthew R. Mackenzie ◽  
Thomas A. Broge ◽  
Evelyn Bord ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Bk Polyomavirus ◽  
Immune Factors

scholarly journals URINE DONOR DERIVED CELL FREE DNA AIDS IN THE DIAGNOSIS OF BK POLYOMAVIRUS NEPHROPATHY IN KIDNEY TRANSPLANT RECIPIENTS WITH BK VIRURIA

2020 ◽  
Vol 104 (S3) ◽  
pp. S367-S368
Author(s):  
Gang Huang ◽  
Xu-Tao Chen ◽  
Wen-Fang Chen ◽  
Pei-Song Chen ◽  
Ting-Ya Jiang ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cell Free Dna ◽  
Free Dna ◽  
Bk Polyomavirus ◽  
Urine Donor

scholarly journals Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1055
Author(s):  
Julien Marlet ◽  
Philippe Gatault ◽  
Zoha Maakaroun ◽  
Hélène Longuet ◽  
Karl Stefic ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Kidney Transplant ◽  
Lymphocytic Leukemia ◽  
Antibody Responses ◽  
Moderate Increase ◽  
Immunocompromised Patients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
The Impact

The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG ≥ 7.1 and ≥ 30 BAU/mL after the third dose were 47% (75/160) and 39% (63/160) in kidney transplant recipients, and 57% (29/51) and 50% (10/20) in patients treated for CLL. Longitudinal follow-up identified a moderate increase in SARS-CoV-2 anti-spike IgG levels after a third dose of vaccine in kidney transplant recipients (0.19 vs. 5.28 BAU/mL, p = 0.03) and in patients treated for CLL (0.63 vs. 10.7 BAU/mL, p = 0.0002). This increase in IgG levels had a limited impact on prevalence of anti-spike IgG ≥ 30 BAU/mL in kidney transplant recipients (17%, 2/12 vs. 33%, 4/12, p = 0.64) and in patients treated for CLL (5%, 1/20 vs. 45%, 9/20, p = 0.008). These results highlight the need for vaccination of the general population and the importance of non-medical preventive measures to protect immunocompromised patients.

Sign in / Sign up

Export Citation Format

Share Document